SCHEMBL3237409

SCHEMBL3237409

Fc1ccc(Nc2cc(-c3ccccc3)nc(Cl)n2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.67
TP53 P04637 5/20 0.67
LMNA P02545 3/20 0.67
THRB P10828 1/20 0.67
AGPAT2 O15120 2/20 0.59
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
HPGD P15428 3/20 0.56
ALDH1A1 P00352 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
POLB P06746 1/20 0.55
ABCG2 Q9UNQ0 2/20 0.51
TXN P10599 1/20 0.50
KDM4E B2RXH2 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
CALCA P06881 1/20 0.46
GPR119 Q8TDV5 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21765569 0.91 MEN1 (0.63) MAPTTP53LMNATHRBAGPAT2
SCHEMBL433520 0.84 MAPT (0.52) MAPTTP53LMNATHRBAGPAT2
SCHEMBL21750705 0.83 MAPT (0.58) MAPTTP53LMNATHRBAGPAT2
SCHEMBL20550985 0.83 MAPT (0.58) MAPTTP53LMNATHRBAGPAT2
SCHEMBL3235329 0.81 MAPT (0.55) MAPTTP53LMNATHRBAGPAT2
SCHEMBL13950492 0.80 MAPT (0.64) MAPTTP53LMNATHRBAGPAT2
SCHEMBL28252052 0.80 MEN1 (0.80) MAPTTP53THRBMEN1KMT2A
SCHEMBL4880624 0.79 TXN (0.53) MAPTTP53LMNATHRBAGPAT2
SCHEMBL20550980 0.78 MAPT (0.75) MAPTTP53MEN1KMT2AHPGD
SCHEMBL30857514 0.78 MAPT (0.75) MAPTTP53MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
WO-2010028179-A1 HETEROCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144722-A1 NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS GATAD2B, GATAD2A, RUNX1 MAPT 4861/4885TP53 943/4885LMNA 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.